Enanta Pharmaceuticals, Inc. (ENTA)
11.47
+0.29
(+2.59%)
USD |
NASDAQ |
Oct 15, 16:00
11.45
-0.02
(-0.17%)
After-Hours: 20:00
Enanta Pharmaceuticals Cash from Operations (TTM) : -35.32M for June 30, 2026
Cash from Operations (TTM) Chart
Historical Cash from Operations (TTM) Data
| Date | Value |
|---|---|
| June 30, 2026 | -35.32M |
| March 31, 2026 | -7.838M |
| December 31, 2025 | -14.17M |
| September 30, 2025 | -19.27M |
| June 30, 2025 | -23.18M |
| March 31, 2025 | -55.46M |
| December 31, 2024 | -70.58M |
| September 30, 2024 | -78.76M |
| June 30, 2024 | -89.97M |
| March 31, 2024 | -107.32M |
| December 31, 2023 | -92.50M |
| September 30, 2023 | -103.15M |
| June 30, 2023 | -97.09M |
| March 31, 2023 | -94.56M |
| December 31, 2022 | -107.15M |
| September 30, 2022 | -84.78M |
| June 30, 2022 | -90.27M |
| March 31, 2022 | -90.17M |
| December 31, 2021 | -68.38M |
| September 30, 2021 | -70.00M |
| June 30, 2021 | -64.44M |
| March 31, 2021 | -39.42M |
| December 31, 2020 | -20.16M |
| September 30, 2020 | 7.088M |
| June 30, 2020 | 31.09M |
| Date | Value |
|---|---|
| March 31, 2020 | 38.12M |
| December 31, 2019 | 53.53M |
| September 30, 2019 | 71.42M |
| June 30, 2019 | 91.21M |
| March 31, 2019 | 92.73M |
| December 31, 2018 | 55.06M |
| September 30, 2018 | 29.22M |
| June 30, 2018 | 58.18M |
| March 31, 2018 | 49.34M |
| December 31, 2017 | 53.92M |
| September 30, 2017 | 52.65M |
| June 30, 2017 | -6.779M |
| March 31, 2017 | -4.095M |
| December 31, 2016 | 8.961M |
| September 30, 2016 | 35.81M |
| June 30, 2016 | 35.56M |
| March 31, 2016 | 23.47M |
| December 31, 2015 | 112.28M |
| September 30, 2015 | 76.67M |
| June 30, 2015 | 74.12M |
| March 31, 2015 | 123.43M |
| December 31, 2014 | 20.44M |
| September 30, 2014 | 20.18M |
| June 30, 2014 | 22.61M |
| March 31, 2014 | -18.43M |
Cash From Operations Definition
Represents the net cash flow from the company's business operations.
Cash from Operations (TTM) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Cash from Operations (TTM) Benchmarks
| Perspective Therapeutics, Inc. | -93.07M |
| Coherus Oncology, Inc. | -186.03M |
| BridgeBio Pharma, Inc. | -434.37M |
| RenovoRx, Inc. | -11.87M |
| ACADIA Pharmaceuticals, Inc. | 160.32M |